Enzon Pharmaceuticals Files Q1 2025 10-Q
Ticker: ENZN · Form: 10-Q · Filed: May 9, 2025 · CIK: 727510
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Enzon Pharma's Q1 2025 10-Q is in. Check preferred stock & R&D.
AI Summary
Enzon Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations. Key financial data points and disclosures related to preferred stock and research activities are included.
Why It Matters
This filing provides investors with an update on Enzon Pharmaceuticals' financial health and operational status for the first quarter of 2025, crucial for investment decisions.
Risk Assessment
Risk Level: low — The filing is a routine quarterly report and does not indicate any immediate or significant risks.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-05-09 — Filing Date (The date the report was officially submitted to the SEC.)
Key Players & Entities
- ENZON PHARMACEUTICALS, INC. (company) — Filer
- 20250331 (date) — Period of Report
- 20250509 (date) — Filing Date
- SeriesCPreferredStockMember (financial_item) — Preferred Stock Series
FAQ
What is the primary business of Enzon Pharmaceuticals, Inc.?
Enzon Pharmaceuticals, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
What is the fiscal year end for Enzon Pharmaceuticals?
The fiscal year end for Enzon Pharmaceuticals is December 31 (1231).
What is the state of incorporation for Enzon Pharmaceuticals?
Enzon Pharmaceuticals, Inc. is incorporated in Delaware (DE).
What specific type of preferred stock is mentioned in relation to Enzon Pharmaceuticals?
The filing mentions 'SeriesCPreferredStockMember' in relation to Enzon Pharmaceuticals' preferred stock.
What is the business address of Enzon Pharmaceuticals?
The business address is 20 Commerce Drive, Suite 135, Cranford, NJ 07016.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding ENZON PHARMACEUTICALS, INC. (ENZN).